UroGen Pharma Ltd. Finance Lease, Principal Payments
UroGen Pharma Ltd. (URGN) reported Finance Lease, Principal Payments of $708.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-05
- UroGen Pharma Ltd. finance lease, principal payments for the quarter ending 2026-06-30 was $387.00K.
- UroGen Pharma Ltd. finance lease, principal payments for the quarter ending 2026-03-31 was $321.00K, a 53.34% decline year-over-year.
- UroGen Pharma Ltd. finance lease, principal payments for the quarter ending 2025-12-31 was -$175.00K.
- UroGen Pharma Ltd. finance lease, principal payments for the quarter ending 2025-09-30 was $1.34M.
- UroGen Pharma Ltd. finance lease, principal payments for fiscal 2025 was $1.85M.
- UroGen Pharma Ltd. finance lease, principal payments for fiscal 2024 was $0.00.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 6 month as first filed | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $387.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $708.00K 10-Q · filed 2026-08-05 | $533.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.88M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $321.00K 10-Q · filed 2026-05-06 | $146.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.49M derived: sum of 3 quarters · filed 2026-05-06 | $1.49M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | -$175.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.17M derived: sum of 2 quarters · filed 2026-03-02 | $1.17M derived: sum of 3 quarters · filed 2026-08-05 | $1.85M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.34M derived: sum of 2 quarters · filed 2026-08-05 | $2.03M 10-Q · filed 2025-11-06 | $2.03M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $688.00K 10-Q · filed 2026-08-05 | $1.33M 10-Q · filed 2025-08-07 | $688.00K derived: sum of 3 quarters · filed 2026-08-05 | $688.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $688.00K 10-Q · filed 2026-05-06 | $688.00K derived: sum of 2 quarters · filed 2026-05-06 | $688.00K derived: sum of 3 quarters · filed 2026-05-06 | $688.00K derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |